doi:10.1152/physrev.00034.2006 Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W
Ideal candidates for leading with NAD+: Patients over 40 experiencing persistent fatigue that does not resolve with sleep or lifestyle changes Individuals with metabolic syndrome, insulin resistance, or difficulty managing weight despite dietary effort Patients recovering from substance use, where NAD+ IV therapy has shown measurable benefit in reducing withdrawal symptoms and cravings High-performance athletes or executives seeking cognitive edge and faster physical recovery Patients with early neurodegenerative concerns who want evidence-supported mitochondrial support GHK-Cu Dosage and NAD+ Dosage: What Clinical Protocols Actually Use Dosing varies based on delivery route, patient body weight, and clinical goal
While not approved for human or veterinary use, AHK-Cu continues to generate strong interest as a research compound across cellular and tissue model studies
Ask about prior authorization requirements and copay amounts
Kilberg MS, Haeussinger D, eds: Mammalian Amino Acid Transport
